(0.80%) 5 277.51 points
(1.51%) 38 686 points
(-0.01%) 16 735 points
(-0.47%) $76.63
(3.36%) $2.67
(0.02%) $2 346.30
(0.61%) $30.63
(0.43%) $1 046.50
(0.03%) $0.922
(0.20%) $10.51
(-0.04%) $0.785
(-0.08%) $90.36
4 days till quarter result
(amc 2024-06-06)
Expected move: +/- 6.28%
@ $21.69
发出时间: 14 Feb 2024 @ 22:30
回报率: 4.93%
上一信号: Feb 13 - 22:30
上一信号:
回报率: -1.99 %
Live Chart Being Loaded With Signals
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally...
Stats | |
---|---|
今日成交量 | 568 310 |
平均成交量 | 716 528 |
市值 | 2.06B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-0.100 ) 2024-06-06 |
Last Dividend | $1.750 ( 2009-07-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.13 |
ATR14 | $0.0190 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-13 | Diaz Paul J | Sell | 57 844 | Common Stock |
2024-05-14 | Diaz Paul J | Sell | 95 000 | Common Stock |
2024-05-15 | Diaz Paul J | Sell | 75 000 | Common Stock |
2024-05-13 | Newcomer Lee Nisley | Sell | 6 200 | Common Stock |
2024-04-14 | Muzzey Dale | Sell | 940 | Common Stock |
INSIDER POWER |
---|
29.41 |
Last 96 transactions |
Buy: 1 118 283 | Sell: 611 851 |
音量 相关性
Myriad Genetics Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Myriad Genetics Inc 相关性 - 货币/商品
Myriad Genetics Inc 财务报表
Annual | 2022 |
营收: | $678.40M |
毛利润: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2022 |
营收: | $678.40M |
毛利润: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2021 |
营收: | $690.60M |
毛利润: | $493.00M (71.39 %) |
EPS: | $-0.350 |
FY | 2020 |
营收: | $638.60M |
毛利润: | $452.50M (70.86 %) |
EPS: | $-2.69 |
Financial Reports:
No articles found.
Myriad Genetics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1.750 | 2009-06-15 |
Last Dividend | $1.750 | 2009-07-01 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $3.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.02 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $3.50 | 10.20% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
OXLC | Dividend Diamond | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend Royal | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.374 | 1.500 | -7.47 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.239 | 1.200 | -7.96 | -9.55 | [0 - 0.3] |
returnOnEquityTTM | -0.350 | 1.500 | -5.00 | -7.49 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.268 | 0.800 | 8.66 | 6.93 | [1 - 3] |
quickRatioTTM | 0.963 | 0.800 | 9.04 | 7.23 | [0.8 - 2.5] |
cashRatioTTM | 0.363 | 1.500 | 9.09 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -93.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.846 | -1.692 | [0 - 20] |
debtEquityRatioTTM | 0.295 | -1.500 | 8.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.689 | 1.000 | 1.852 | 1.852 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.370 | 1.000 | -9.41 | -9.41 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.317 | 1.000 | -2.87 | -2.87 | [0.2 - 2] |
assetTurnoverTTM | 0.639 | 0.800 | 9.07 | 7.26 | [0.5 - 2] |
Total Score | -0.0149 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.78 | 1.000 | -0.786 | 0 | [1 - 100] |
returnOnEquityTTM | -0.350 | 2.50 | -3.21 | -7.49 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.564 | -1.692 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0700 | 1.500 | -2.87 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0870 | 1.000 | -4.68 | 0 | [0.1 - 0.5] |
Total Score | -1.944 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Myriad Genetics Inc
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。